1. 1. Middle East Respiratory Syndrome (MERS) 1 2015.6.13
2. 2. 2012/6/13 60 7 11 2012/9/21 2012/9/23 WHO 2012/9 49 2 2012MERS
3. 3. 2015/6/91219449 3
4. 4. MERS 4 Update2015/06 WHO6/925916
5. 5. 5 >1,000
6. 6. 15 23 6 / 2 2 3 1 1 2 1 1 1 1 2 1 ( ) 2 1 2 2 1 1 2 15 23 6 6 137 131624141 613
7. 7. 7 612
8. 8. 8 WHO611 MERS
9. 9. Nat Rev Microbiol 2013;11:836-48. MERS-CoV SARS 9 MERS
10. 10. 10 MERS SARS
11. 11. MERS MERS MERS 90%MERSMERS MERS MERS 15-23 11
12. 12. MERS SARSMERS 12
13. 13. : 71% (40%-98%) 68% 66% 32% MERS(64%)(17%) (14%)(12%)(9%)(9%) MERS4% 13 MERS (N=58) 52 (90%) 20 (34%) 13 (22%) 11 (19%)
14. 14. 38 MERS MERS 14 69 14
15. 15. 15
16. 16. 16
17. 17. 17
18. 18. 18 MERS 14 5/11 5/11 MERS-CoV MERS-CoV MERS-CoV MERS 69
19. 19. 19
20. 20. MERS -MERS - - -40% - - -26 660 - - 62 20
21. 21. 2003 SARS 2009 H1N1 2012 MERS 2013 H7N9 2014 21
22. 22.
23. 23. WHO IHR Focal Point 0 100 200 300 400 500 600 '08/31 39 47 3 11 19 27 35 43 51 6 14 22 0 10 20 30 40 50 60 70 80 90 100 B AH1 AH3 Pandemic (H1N1) 2009 A Flu positive rate Week received Flupositiverate Isolates The latest 3 weeks: Percentage of novel flu among ILI= 9% (6,12) Oseltamivir-resistant Virus: 8/ 1158 (0.69%) 11588 A/California/07/2009-likeVirus: 113/113 (100%) 113 A/California/07/2009 23
24. 24. 12()real-time RT-PCR MERS 1.real-time RT-PCR 2.MERS 3.MERS real-time RT-PCR - MERS 24
25. 25. / / /
26. 26. 2015/6/14 26 (29 ) - (34 ) (20 ) (22 ) (7 ) (9 ) 104 6134 6 -
27. 27. - MERS
28. 28. - 28 * N95 80.0 21.3 91.1 192.4 30.0 6.0 16.3 52.3 903.9 183.2 3,161.9 4,249
29. 29. IHR MERS CDC 528 CDC
30. 30. 192224
31. 31. MERS MERS 69 31
32. 32. 32